Fundamental Analysis of GreenLight Biosciences Holdings PBC(NASDAQ:GRNA) stock

Fundamental Rating

Overall GRNA gets a fundamental rating of 2 out of 10. We evaluated GRNA against 588 industry peers in the Biotechnology industry. GRNA may be in some trouble as it scores bad on both profitability and health. GRNA shows excellent growth, but is valued quite expensive already.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year GRNA has reported negative net income.

In the past year GRNA has reported a negative cash flow from operations.

1.2 Ratios

The profitability ratios for GRNA are negative, so there is not much use analyzing them.

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

GRNA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

GRNA does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, GRNA has more shares outstanding

Compared to 1 year ago, GRNA has an improved debt to assets ratio.

2.2 Solvency

GRNA has an Altman-Z score of -9.56. This is a bad value and indicates that GRNA is not financially healthy and even has some risk of bankruptcy.

The Altman-Z score of GRNA (-9.56) is worse than 80.98% of its industry peers.

GRNA has a Debt/Equity ratio of 0.49. This is a healthy value indicating a solid balance between debt and equity.

Looking at the Debt to Equity ratio, with a value of 0.49, GRNA is doing worse than 76.40% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.49
Debt/FCF	N/A
Altman-Z	-9.56

ROIC/WACCN/A

WACC8.59%

2.3 Liquidity

GRNA has a Current Ratio of 1.21. This is a normal value and indicates that GRNA is financially healthy and should not expect problems in meeting its short term obligations.

The Current ratio of GRNA (1.21) is worse than 90.15% of its industry peers.

GRNA has a Quick Ratio of 1.21. This is a normal value and indicates that GRNA is financially healthy and should not expect problems in meeting its short term obligations.

GRNA has a worse Quick ratio (1.21) than 89.13% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.21
Quick Ratio	1.21

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for GRNA have decreased by -5.79% in the last year.

The Revenue has grown by 577.34% in the past year. This is a very strong growth!

GRNA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 31.22% yearly.

EPS 1Y (TTM)-5.79%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q44.19%

Revenue 1Y (TTM)577.34%

Revenue growth 3Y31.22%

Revenue growth 5YN/A

Revenue growth Q2Q1386.38%

3.2 Future

GRNA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.95% yearly.

GRNA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 157.83% yearly.

EPS Next Y26.28%

EPS Next 2Y12.95%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year167.93%

Revenue Next 2Y157.83%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GRNA. In the last year negative earnings were reported.

Also next year GRNA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as GRNA's earnings are expected to grow with 12.95% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y12.95%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

GRNA does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

GreenLight Biosciences Holdings PBC

NASDAQ:GRNA (7/21/2023, 7:00:02 PM)

After market: 0.2995 0 (0%)

0.2995

0 (-0.03%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap45.43M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.09

Health

		Industry Rank	Sector Rank
Debt/Equity	0.49
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	1.21
Quick Ratio	1.21
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-5.79%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y26.28%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)577.34%

Revenue growth 3Y31.22%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

GreenLight Biosciences Holdings PBC (GRNA)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens